Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar:53:102304.
doi: 10.1016/j.tranon.2025.102304. Epub 2025 Feb 7.

Currents status of radiotracers for breast cancer imaging in PET

Chloé Jean  1 , Stéphane Roux  2 , Abdelilah Aziz  3 , Maxence Mocquery-Corre  3 , Rana Bazzi  2 , Yacine Merrouche  4 , Stéphane Dedieu  3 , Nicolas Etique  3 , Dimitri Papathanassiou  5 , Jérôme Devy  6
Affiliations
Review

Currents status of radiotracers for breast cancer imaging in PET

Chloé Jean et al. Transl Oncol. 2025 Mar.

Abstract

Radiolabeled molecules have become valuable tools in the diagnosis, monitoring, and treatment of cancer, particularly breast cancer. Through the use of radiotracers, clinicians can target specific tumor cells, assess microenvironments, and identify metastases. These radiopharmaceuticals, based on radionuclides, enable both imaging and therapeutic applications, leading to personalized cancer treatment. Techniques such as PET, SPECT, and the use of nanoparticles for theranostics are at the forefront of innovation, offering improved precision in both diagnosis and therapy. This review explores the various ways in which radiotracers are leveraged in modern oncology, with a focus on breast cancer, and highlights recent advancements in targeted radionuclide therapy and nanoparticle-based applications.

Keywords: Breast cancer; Nanoparticles; Radiopharmaceuticals; Radiotracers; Targeted radionuclide therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that couId have appeared to influence the work reported in this paper.

Figures

Image, graphical abstract
Graphical abstract
See this image and copyright information in PMC

References

    1. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 2022;72(6):524‑41. - PubMed
    1. Courtney D, Davey MG, Moloney BM, Barry MK, Sweeney K, McLaughlin RP, et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir. J. Med. Sci. 2022;191(6):2501‑10. - PMC - PubMed
    1. Crișan G, Moldovean-Cioroianu NS, Timaru DG, Andrieș G, Căinap C, Chiș V. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int. J. Mol. Sci. 2022;23(9):5023. - PMC - PubMed
    1. SY Chae, Park SH, Lee HS, Ahn JH, Kim SB, Jung KH, et al. Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Sci. Rep. 2022;12(1):7858. - PMC - PubMed
    1. Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res. 2008;10(1):S3. - PMC - PubMed

LinkOut - more resources